gp209-2M-sensitized autologous lymphocytes

gp209-2M-sensitized autologous lymphocytes are a form of adoptive cell therapy (ACT) developed primarily at the National Cancer Institute (NCI) for the treatment of HLA-A*0201-positive patients with metastatic melanoma. This personalized immunotherapy involves harvesting a patient's peripheral blood mononuclear cells (PBMCs) or tumor-infiltrating lymphocytes (TILs) and stimulating them ex vivo with a synthetic, modified peptide derived from the melanoma-associated antigen gp100. The specific peptide used, gp209-2M (sequence: IMDQVPFSV), is an altered peptide ligand of the native gp100:209-217 epitope (ITDQVPFSV); the substitution of threonine with methionine at the second position significantly enhances its binding affinity for the HLA-A2 molecule. This modification facilitates the more efficient activation and selective expansion of CD8+ cytotoxic T cells that can recognize the naturally occurring gp100 epitopes on the surface of melanoma cells. Following ex vivo expansion, typically in the presence of interleukin-2 (IL-2), the sensitized lymphocytes are re-infused into the patient where they mediate tumor cell lysis through T-cell receptor (TCR) recognition of the gp100 antigen.

Other names

gp209-2M sensitized T cellsgp-209-2M sensitized T cellsgp 209-2M sensitized T cellsgp100:209-217(210M)-sensitized autologous lymphocytesg209-2M-sensitized lymphocytesg-209-2M-sensitized lymphocytesg 209-2M-sensitized lymphocytesautologous gp209-2M-reactive T cells